Trials / Completed
CompletedNCT03919994
Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
OASIS: Observational Study of LAIs In Schizophrenia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 338 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to describe characteristics, treatment patterns, and outcomes of patients with schizophrenia newly initiated on 1 of 4 FDA-approved atypical Long Acting Injectable (LAI) antipsychotics (ABILIFY MAINTENA®, ARISTADA®, INVEGA SUSTENNA® or RISPERDAL CONSTA®)
Detailed description
This is a non-interventional, prospective, multi-center observational cohort study. Patients at behavioral health clinics will be enrolled and evaluated by health care professionals (e.g., psychiatrists) according to the standard of care. All patients will be followed for approximately 12 months from their enrollment visit.
Conditions
Timeline
- Start date
- 2019-03-28
- Primary completion
- 2023-01-04
- Completion
- 2023-01-04
- First posted
- 2019-04-18
- Last updated
- 2023-02-02
Locations
57 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03919994. Inclusion in this directory is not an endorsement.